
Eliglustat capsule
Form: Capsules
Strength: 84 mg
Reference Brands: Cerdelga®(US & EU)
Category: Orphan Drugs
Eliglustat capsules, marketed as Cerdelga®, are approved for treating Gaucher disease type 1 in both the US and EU. The FDA and EMA reviewed comprehensive regulatory dossiers, including clinical trial data, manufacturing standards, and safety profiles, to ensure high-quality standards. These dossiers support regulatory approval and facilitate market access. Cerdelga® capsules are available in an 84 mg strength, offering an effective oral therapy option. For detailed information on the regulatory process, dossier submissions, and market approvals, visit PharmaTradz, your source for pharmaceutical regulatory insights and updates.
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Related Products
Galsulfase IV
Strength: 1mg/ml
Form: Lyophilized powder for IV
Reference Brands: Vimizim®(US & EU)
View Details Get EnquiryAlglucosidase Alfa IV
Strength: 50 mg/vial
Form: Lyophilized powder
Reference Brands: Lumizyme®(US & EU)
View Details Get EnquiryNitisinone tablets
Strength: 2 mg and 5 mg
Form: Tablets
Reference Brands: Orfadin®
View Details Get EnquiryTreprostinil IV or SC
Strength: 2 mg (0.1 mg/mL), 4 mg (0.2 mg/mL), 8 mg (0.4 mg/mL), 20 mg (1 mg/mL), 50 mg (2.5 mg/mL), 100 mg (5 mg/mL), 200 mg (10 mg/mL), or 400 mg (20 mg/mL)
Form: SC or Intravenous (IV)
Reference Brands: Remodulin®(US & EU)
View Details Get Enquiry